Accelerating CB1, CB2 & Cannabinoid Approvals in Obesity, Pain, CNS & Inflammation

As drug developers continue to utilize the expedited FDA regulatory pathway available for CBD, alongside a growing interest in the therapeutic benefits and regulatory approval of novel cannabinoids, the cannabinoid drug development landscape is rapidly evolving. Additionally, innovative preclinical candidates targeting CB1 and CB2 receptors are advancing through the pipeline, as developers aim to secure regulatory approval for treatments addressing weight management, pain, neurological conditions, and more.

The field continues to grow, with both phytocannabinoid and synthetic drug candidates aspiring to achieve milestones like those set by Epidiolex, Marinol, Syndros, and Cesamet.

The 7th CB1, CB2, & Cannabinoid Drug Development Summit offered:

• Innovative Research Insights: Attendees discovered the latest advancements in cannabinoid and ECS-targeting research, highlighting breakthroughs in preclinical and clinical studies.
• Expert Panels: We engaged with 18+ expert speakers from top companies, sharing their latest research challenges and innovative approaches.
• Regulatory Deep Dives: We participated in in-depth discussions on navigating the evolving regulatory landscape and securing approvals for cannabinoid therapies.
• Success Stories: Attendees examined case studies of successful cannabinoid drug developments and ongoing clinical trials, with a focus on efficacy and safety.
• Trial Design Evaluations: We assessed cutting-edge clinical trial designs, including considerations for safety, efficacy, and dosage.

Over 60 experts from discovery, preclinical, translational, regulatory, clinical, and chemistry fields came together as they worked to unlock the potential of CB1, CB2, and cannabinoid drugs for treating obesity, pain, inflammation, CNS disorders, and rare diseases.